CHRS stock forecast
Our latest prediction for Coherus BioSciences, Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 19.25$.
In the short term (2weeks), CHRS's stock price should underperform the market by -0.45%. During that period the price should oscillate between -9.91% and +8.26%.
In the medium term (3months), CHRS's stock price should underperform the market by -3.80%. During that period the price should oscillate between -26.29% and +19.67%.Get email alerts
Create a solid portfolio with CHRS
About Coherus BioSciences, Inc.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
At the moment the company generates 435M USD in revenues.
On its last earning announcement, the company reported a profit of 2.00$ per share.
The book value per share is 0.93$
Three months stock forecastNov. 20, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|